Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatectomy | 54 | 2020 | 476 | 4.840 |
Why?
|
Robotics | 44 | 2015 | 268 | 4.500 |
Why?
|
Prostatic Neoplasms | 55 | 2021 | 1763 | 3.120 |
Why?
|
Laparoscopy | 35 | 2020 | 762 | 2.800 |
Why?
|
Erectile Dysfunction | 8 | 2010 | 75 | 0.790 |
Why?
|
Urology | 4 | 2020 | 117 | 0.740 |
Why?
|
Prostate | 10 | 2015 | 391 | 0.720 |
Why?
|
Robotic Surgical Procedures | 4 | 2020 | 294 | 0.620 |
Why?
|
Lymph Node Excision | 3 | 2015 | 221 | 0.600 |
Why?
|
Postoperative Hemorrhage | 2 | 2015 | 46 | 0.570 |
Why?
|
Urinary Incontinence | 6 | 2012 | 213 | 0.570 |
Why?
|
Surgery, Computer-Assisted | 2 | 2015 | 98 | 0.550 |
Why?
|
Middle Aged | 57 | 2020 | 25649 | 0.520 |
Why?
|
Head-Down Tilt | 1 | 2015 | 5 | 0.520 |
Why?
|
Adenocarcinoma | 7 | 2021 | 1184 | 0.510 |
Why?
|
Male | 77 | 2021 | 41953 | 0.510 |
Why?
|
Ear Diseases | 1 | 2015 | 20 | 0.510 |
Why?
|
Urinary Bladder, Neurogenic | 3 | 2011 | 25 | 0.500 |
Why?
|
Clinical Clerkship | 2 | 2007 | 118 | 0.500 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 115 | 0.490 |
Why?
|
Hematoma | 1 | 2015 | 107 | 0.480 |
Why?
|
Aged | 47 | 2021 | 18904 | 0.470 |
Why?
|
Urinary Catheters | 1 | 2014 | 6 | 0.470 |
Why?
|
Urinary Catheterization | 1 | 2014 | 36 | 0.460 |
Why?
|
Drainage | 1 | 2014 | 157 | 0.440 |
Why?
|
Device Removal | 1 | 2014 | 167 | 0.410 |
Why?
|
Urinary Diversion | 2 | 2010 | 42 | 0.410 |
Why?
|
Curriculum | 2 | 2007 | 565 | 0.400 |
Why?
|
Prospective Studies | 20 | 2014 | 4268 | 0.390 |
Why?
|
Sural Nerve | 2 | 2008 | 19 | 0.390 |
Why?
|
Neoplasm Staging | 16 | 2016 | 1982 | 0.390 |
Why?
|
Laparoscopes | 2 | 2008 | 15 | 0.380 |
Why?
|
Seminal Vesicles | 4 | 2021 | 39 | 0.380 |
Why?
|
Humans | 84 | 2021 | 88482 | 0.370 |
Why?
|
Treatment Outcome | 25 | 2020 | 8151 | 0.340 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 2009 | 21 | 0.330 |
Why?
|
Suture Techniques | 6 | 2010 | 138 | 0.330 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2009 | 103 | 0.320 |
Why?
|
Follow-Up Studies | 14 | 2016 | 3653 | 0.310 |
Why?
|
Urination Disorders | 4 | 2008 | 50 | 0.310 |
Why?
|
Retrospective Studies | 18 | 2020 | 8869 | 0.310 |
Why?
|
Preoperative Care | 6 | 2013 | 398 | 0.300 |
Why?
|
Teaching Materials | 1 | 2007 | 14 | 0.300 |
Why?
|
Learning | 2 | 2007 | 283 | 0.300 |
Why?
|
Equipment Failure | 1 | 2007 | 120 | 0.290 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2008 | 394 | 0.270 |
Why?
|
Educational Measurement | 1 | 2007 | 230 | 0.260 |
Why?
|
Postoperative Care | 5 | 2014 | 230 | 0.260 |
Why?
|
Biopsy, Needle | 6 | 2012 | 235 | 0.230 |
Why?
|
Urethra | 2 | 2006 | 115 | 0.220 |
Why?
|
Adult | 29 | 2016 | 26303 | 0.220 |
Why?
|
Urologic Surgical Procedures | 2 | 2017 | 147 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2015 | 1351 | 0.210 |
Why?
|
Postoperative Complications | 11 | 2011 | 2282 | 0.210 |
Why?
|
Carcinoma, Giant Cell | 1 | 2002 | 2 | 0.210 |
Why?
|
Aged, 80 and over | 15 | 2011 | 6713 | 0.210 |
Why?
|
Multivariate Analysis | 8 | 2012 | 994 | 0.210 |
Why?
|
Vaginal Neoplasms | 1 | 2002 | 84 | 0.200 |
Why?
|
Disease-Free Survival | 6 | 2015 | 1213 | 0.200 |
Why?
|
Appendix | 3 | 2011 | 31 | 0.200 |
Why?
|
Cystadenoma | 1 | 2021 | 19 | 0.200 |
Why?
|
Prostate-Specific Antigen | 8 | 2013 | 358 | 0.190 |
Why?
|
Penile Erection | 1 | 2000 | 22 | 0.190 |
Why?
|
Margins of Excision | 1 | 2020 | 39 | 0.190 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2000 | 30 | 0.190 |
Why?
|
Clinical Competence | 3 | 2015 | 779 | 0.180 |
Why?
|
Workload | 1 | 2020 | 129 | 0.170 |
Why?
|
Urethral Diseases | 1 | 1999 | 15 | 0.170 |
Why?
|
Ossification, Heterotopic | 1 | 1999 | 33 | 0.170 |
Why?
|
Pelvis | 3 | 2015 | 94 | 0.170 |
Why?
|
Pelvic Bones | 1 | 1999 | 42 | 0.170 |
Why?
|
Phimosis | 1 | 1998 | 1 | 0.160 |
Why?
|
Time Factors | 8 | 2014 | 5309 | 0.160 |
Why?
|
Piperazines | 1 | 2000 | 280 | 0.160 |
Why?
|
Biopsy | 9 | 2016 | 1187 | 0.160 |
Why?
|
Proportional Hazards Models | 4 | 2015 | 858 | 0.160 |
Why?
|
Surveys and Questionnaires | 8 | 2010 | 2590 | 0.160 |
Why?
|
Nomograms | 2 | 2008 | 29 | 0.160 |
Why?
|
Anastomosis, Surgical | 5 | 2011 | 273 | 0.160 |
Why?
|
Spermine | 1 | 1998 | 21 | 0.150 |
Why?
|
Urinary Bladder Neck Obstruction | 3 | 2008 | 21 | 0.150 |
Why?
|
Fractures, Bone | 1 | 1999 | 123 | 0.150 |
Why?
|
Lymphatic Metastasis | 3 | 2015 | 499 | 0.150 |
Why?
|
Health Plan Implementation | 1 | 2017 | 56 | 0.140 |
Why?
|
Urologic Diseases | 1 | 2017 | 45 | 0.140 |
Why?
|
Tertiary Care Centers | 1 | 2017 | 101 | 0.140 |
Why?
|
Urinary Bladder | 2 | 2010 | 246 | 0.140 |
Why?
|
Overweight | 2 | 2008 | 118 | 0.140 |
Why?
|
Child | 8 | 2017 | 7081 | 0.130 |
Why?
|
Carcinoma, Ductal | 1 | 2015 | 18 | 0.130 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2015 | 11 | 0.130 |
Why?
|
Ear Canal | 1 | 2015 | 14 | 0.130 |
Why?
|
Learning Curve | 1 | 2015 | 18 | 0.130 |
Why?
|
Probability | 4 | 2010 | 356 | 0.130 |
Why?
|
General Surgery | 2 | 2008 | 235 | 0.120 |
Why?
|
Operative Time | 1 | 2015 | 138 | 0.120 |
Why?
|
Logistic Models | 5 | 2011 | 1204 | 0.120 |
Why?
|
Population Surveillance | 1 | 2015 | 217 | 0.120 |
Why?
|
Neoplasm Grading | 4 | 2016 | 367 | 0.120 |
Why?
|
Predictive Value of Tests | 7 | 2016 | 1704 | 0.110 |
Why?
|
Age Factors | 6 | 2013 | 1860 | 0.110 |
Why?
|
Neoplasm Invasiveness | 3 | 2016 | 575 | 0.110 |
Why?
|
Antineoplastic Agents | 2 | 2011 | 2405 | 0.110 |
Why?
|
Organ Size | 3 | 2010 | 367 | 0.110 |
Why?
|
Brachytherapy | 2 | 2004 | 121 | 0.100 |
Why?
|
Diagnostic Errors | 1 | 2013 | 160 | 0.100 |
Why?
|
Incidence | 5 | 2015 | 1588 | 0.100 |
Why?
|
Anticoagulants | 1 | 2015 | 423 | 0.100 |
Why?
|
Ileum | 2 | 2010 | 162 | 0.100 |
Why?
|
Pain, Postoperative | 1 | 2014 | 247 | 0.100 |
Why?
|
Chemoprevention | 1 | 2011 | 92 | 0.100 |
Why?
|
Urinary Reservoirs, Continent | 1 | 2011 | 14 | 0.100 |
Why?
|
Kidney | 3 | 2009 | 1145 | 0.100 |
Why?
|
Ostomy | 1 | 2011 | 15 | 0.100 |
Why?
|
Quality of Life | 3 | 2008 | 1647 | 0.100 |
Why?
|
Apoptosis | 1 | 1998 | 1716 | 0.100 |
Why?
|
Cystostomy | 1 | 2011 | 15 | 0.100 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2010 | 23 | 0.090 |
Why?
|
Physicians | 2 | 2009 | 684 | 0.090 |
Why?
|
Urodynamics | 3 | 2008 | 122 | 0.090 |
Why?
|
Frozen Sections | 1 | 2010 | 48 | 0.090 |
Why?
|
Risk Assessment | 5 | 2012 | 2285 | 0.090 |
Why?
|
Immediate-Early Proteins | 1 | 2011 | 166 | 0.090 |
Why?
|
Carcinoma | 1 | 2013 | 441 | 0.090 |
Why?
|
Nephrectomy | 3 | 2007 | 293 | 0.090 |
Why?
|
Wolffian Ducts | 1 | 2009 | 7 | 0.080 |
Why?
|
Femoral Artery | 1 | 2009 | 83 | 0.080 |
Why?
|
Anesthesia | 2 | 2009 | 169 | 0.080 |
Why?
|
Intraoperative Complications | 2 | 2009 | 188 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2008 | 479 | 0.080 |
Why?
|
Reoperation | 2 | 2009 | 605 | 0.080 |
Why?
|
Radioimmunodetection | 1 | 2008 | 13 | 0.080 |
Why?
|
Creatinine | 1 | 2009 | 295 | 0.080 |
Why?
|
Neuromuscular Diseases | 1 | 2008 | 30 | 0.080 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2009 | 120 | 0.080 |
Why?
|
Perioperative Care | 1 | 2009 | 167 | 0.080 |
Why?
|
Arthritis | 1 | 2008 | 47 | 0.080 |
Why?
|
Aorta | 1 | 2009 | 286 | 0.080 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2008 | 69 | 0.080 |
Why?
|
Prognosis | 5 | 2016 | 3749 | 0.080 |
Why?
|
Patient Selection | 1 | 2011 | 689 | 0.080 |
Why?
|
Occupational Diseases | 1 | 2008 | 55 | 0.070 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2009 | 247 | 0.070 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2007 | 9 | 0.070 |
Why?
|
Intestines | 1 | 2010 | 416 | 0.070 |
Why?
|
Medical Illustration | 1 | 2007 | 16 | 0.070 |
Why?
|
Contracture | 1 | 2006 | 18 | 0.070 |
Why?
|
Urologic Neoplasms | 1 | 2007 | 81 | 0.070 |
Why?
|
Urinary Bladder Diseases | 1 | 2006 | 41 | 0.070 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2009 | 223 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2010 | 547 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2008 | 235 | 0.070 |
Why?
|
Cohort Studies | 4 | 2020 | 2833 | 0.070 |
Why?
|
Prostatic Hyperplasia | 2 | 1998 | 91 | 0.070 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2007 | 51 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2007 | 360 | 0.070 |
Why?
|
Fellowships and Scholarships | 1 | 2007 | 119 | 0.070 |
Why?
|
United States | 2 | 2015 | 6877 | 0.060 |
Why?
|
Female | 11 | 2010 | 45687 | 0.060 |
Why?
|
Regression Analysis | 3 | 2013 | 594 | 0.060 |
Why?
|
Carcinoma, Medullary | 1 | 2004 | 11 | 0.060 |
Why?
|
Risk Factors | 5 | 2011 | 5439 | 0.060 |
Why?
|
Analysis of Variance | 3 | 2012 | 902 | 0.060 |
Why?
|
Radiotherapy, Conformal | 1 | 2004 | 84 | 0.060 |
Why?
|
Obesity | 2 | 2008 | 969 | 0.050 |
Why?
|
Survival Rate | 3 | 2015 | 1881 | 0.050 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2004 | 180 | 0.050 |
Why?
|
Child, Preschool | 3 | 2011 | 3671 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2012 | 1790 | 0.050 |
Why?
|
Kidney Neoplasms | 2 | 2007 | 631 | 0.050 |
Why?
|
Genital Neoplasms, Male | 1 | 2021 | 11 | 0.050 |
Why?
|
Sildenafil Citrate | 1 | 2000 | 23 | 0.050 |
Why?
|
Survival Analysis | 2 | 2016 | 1542 | 0.050 |
Why?
|
Sulfones | 1 | 2000 | 45 | 0.050 |
Why?
|
Purines | 1 | 2000 | 93 | 0.050 |
Why?
|
Penis | 1 | 2000 | 58 | 0.040 |
Why?
|
Hot Flashes | 1 | 2000 | 12 | 0.040 |
Why?
|
Leuprolide | 1 | 2000 | 35 | 0.040 |
Why?
|
Health Surveys | 1 | 2000 | 239 | 0.040 |
Why?
|
Algorithms | 2 | 2007 | 1864 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 1998 | 1056 | 0.040 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2000 | 156 | 0.040 |
Why?
|
Estrogens | 1 | 2000 | 201 | 0.040 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 176 | 0.040 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1998 | 65 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2004 | 1256 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2004 | 1427 | 0.040 |
Why?
|
Risk | 2 | 2010 | 660 | 0.040 |
Why?
|
Doxazosin | 1 | 1997 | 1 | 0.040 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 1997 | 31 | 0.040 |
Why?
|
Intraoperative Period | 2 | 2008 | 90 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 409 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 1998 | 397 | 0.040 |
Why?
|
Health Care Rationing | 1 | 2017 | 83 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2010 | 771 | 0.030 |
Why?
|
Plant Extracts | 1 | 1998 | 244 | 0.030 |
Why?
|
Surgical Procedures, Operative | 1 | 1998 | 205 | 0.030 |
Why?
|
Mice, Nude | 1 | 1998 | 814 | 0.030 |
Why?
|
Cell Survival | 1 | 1998 | 980 | 0.030 |
Why?
|
Rats | 2 | 1998 | 4034 | 0.030 |
Why?
|
Adolescent | 3 | 2011 | 9141 | 0.030 |
Why?
|
Relative Biological Effectiveness | 2 | 2004 | 13 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1998 | 1944 | 0.030 |
Why?
|
Biopsy, Large-Core Needle | 1 | 2013 | 14 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2008 | 354 | 0.030 |
Why?
|
Databases, Factual | 1 | 2016 | 846 | 0.030 |
Why?
|
Specimen Handling | 1 | 2013 | 101 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2013 | 252 | 0.030 |
Why?
|
Chicago | 1 | 2016 | 1408 | 0.030 |
Why?
|
Infant | 1 | 1998 | 3113 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2011 | 41 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2011 | 127 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 59 | 0.020 |
Why?
|
Spinal Dysraphism | 1 | 2010 | 19 | 0.020 |
Why?
|
Receptors, Androgen | 1 | 2011 | 121 | 0.020 |
Why?
|
Intraoperative Care | 1 | 2010 | 84 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2004 | 1709 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 863 | 0.020 |
Why?
|
Receptors, Glucocorticoid | 1 | 2011 | 131 | 0.020 |
Why?
|
Life Expectancy | 1 | 2010 | 86 | 0.020 |
Why?
|
Body Mass Index | 1 | 2013 | 768 | 0.020 |
Why?
|
Lymphocele | 1 | 2009 | 6 | 0.020 |
Why?
|
Fasciotomy | 1 | 2009 | 17 | 0.020 |
Why?
|
Vas Deferens | 1 | 2009 | 7 | 0.020 |
Why?
|
Aortography | 1 | 2009 | 64 | 0.020 |
Why?
|
Databases as Topic | 1 | 2009 | 93 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2009 | 226 | 0.020 |
Why?
|
Incidental Findings | 1 | 2009 | 97 | 0.020 |
Why?
|
Calibration | 1 | 2008 | 102 | 0.020 |
Why?
|
Urography | 1 | 2008 | 45 | 0.020 |
Why?
|
Ureter | 1 | 2009 | 93 | 0.020 |
Why?
|
Cystoscopy | 1 | 2008 | 39 | 0.020 |
Why?
|
Area Under Curve | 1 | 2008 | 333 | 0.020 |
Why?
|
Internship and Residency | 1 | 2017 | 1036 | 0.020 |
Why?
|
Mathematics | 1 | 2007 | 191 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 279 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2011 | 1712 | 0.020 |
Why?
|
Swine | 1 | 2009 | 578 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 1586 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2009 | 995 | 0.020 |
Why?
|
Jamaica | 1 | 2007 | 5 | 0.020 |
Why?
|
Mice | 2 | 1998 | 11700 | 0.020 |
Why?
|
Postoperative Period | 1 | 2008 | 306 | 0.020 |
Why?
|
Equipment Design | 1 | 2008 | 415 | 0.020 |
Why?
|
Animals | 3 | 2009 | 27203 | 0.020 |
Why?
|
Demography | 1 | 2007 | 181 | 0.020 |
Why?
|
Odds Ratio | 1 | 2008 | 685 | 0.020 |
Why?
|
Fatty Acids | 1 | 2007 | 131 | 0.020 |
Why?
|
Dietary Fats | 1 | 2007 | 136 | 0.020 |
Why?
|
ROC Curve | 1 | 2008 | 773 | 0.020 |
Why?
|
Acute Disease | 1 | 2007 | 838 | 0.020 |
Why?
|
Recurrence | 1 | 2008 | 1168 | 0.020 |
Why?
|
Gene Library | 1 | 2004 | 133 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2004 | 188 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2004 | 295 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2003 | 471 | 0.010 |
Why?
|
Administration, Cutaneous | 1 | 2000 | 60 | 0.010 |
Why?
|
Disease Progression | 1 | 2004 | 1489 | 0.010 |
Why?
|
Biomarkers, Tumor | 1 | 2007 | 1520 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2009 | 2632 | 0.010 |
Why?
|
Neomycin | 1 | 1998 | 7 | 0.010 |
Why?
|
Karyotyping | 1 | 1998 | 253 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1998 | 116 | 0.010 |
Why?
|
Mice, SCID | 1 | 1998 | 261 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 1998 | 612 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1998 | 1095 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 1998 | 2335 | 0.000 |
Why?
|